婴儿丙泊酚麻醉的脑电指标:一项早期生物标志物探索研究
这项前瞻性研究纳入3至12月龄婴儿,评估频谱边缘频率(SEF95)作为丙泊酚麻醉生物标志物的可行性。研究确定了三种临床终点(安抚奶嘴放置、电刺激、喉镜置入)的SEF95目标范围,并发现SEF95与丙泊酚血浆浓度呈线性负相关。结论认为SEF95可作为婴儿丙泊酚麻醉深度的生物标志物。
要点
- 婴儿丙泊酚麻醉中,不同临床刺激对应不同的SEF95目标值。
- SEF95每升高1 Hz,丙泊酚血浆浓度降低0.24 μg/ml。
- SEF95有望提高婴儿丙泊酚给药的准确性。
核心结论
- SEF95可作为婴儿丙泊酚麻醉深度的生物标志物,可能改善该人群丙泊酚给药的准确性和使用。
研究设计与样本
- 前瞻性研究,纳入3至12月龄婴儿,最终44例可评估(占90%)。
- 采用Dixon上下法确定各临床终点的目标SEF95,用中心等渗回归确定ED50和ED90,用线性混合效应模型分析丙泊酚血浆浓度与SEF95的关联。
主要发现
- 安抚奶嘴放置终点的SEF95 ED50为21.4 Hz,ED90为19.3 Hz。
- 电刺激终点的SEF95 ED50为12.6 Hz,ED90为10.4 Hz。
- 喉镜置入终点的SEF95 ED50为8.5 Hz,ED90为5.2 Hz。
- 丙泊酚血浆浓度在0.5至6 μg/ml范围内,SEF95每升高1 Hz,血浆丙泊酚浓度降低0.24 μg/ml(95%CI 0.19至0.29;P < 0.001;边际R2 = 0.55)。
关键数值与推荐
- 安抚奶嘴放置:SEF95 ED50为21.4 Hz,ED90为19.3 Hz。
- 电刺激:SEF95 ED50为12.6 Hz,ED90为10.4 Hz。
- 喉镜置入:SEF95 ED50为8.5 Hz,ED90为5.2 Hz。
- SEF95与丙泊酚血浆浓度呈线性负相关:每1 Hz升高对应0.24 μg/ml降低(95%CI 0.19至0.29;P < 0.001)。
临床怎么用
- 婴儿丙泊酚麻醉中可参考SEF95目标值来评估不同临床刺激下的麻醉深度。
- SEF95与丙泊酚血浆浓度的线性关系可用于辅助调整给药。
局限性
- 研究为早期生物标志物探索,样本量有限(44例可评估)。
- 仅评估了SEF95,未与其他专有脑电指数比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Unlike expired sevoflurane concentration, propofol lacks a biomarker for its brain effect site concentration, leading to dosing imprecision particularly in infants. Electroencephalography monitoring can serve as a biomarker for propofol effect site concentration, yet proprietary electroencephalography indices are not validated in infants. The authors evaluated spectral edge frequency (SEF95) as a propofol anesthesia biomarker in infants. It was hypothesized that the SEF95 targets will vary for different clinical stimuli and an inverse relationship existed between SEF95 and propofol plasma concentration. METHODS: This prospective study enrolled infants (3 to 12 months) to determine the SEF95 ranges for three clinical endpoints of anesthesia (consciousness-pacifier placement, pain-electrical nerve stimulation, and intubation-laryngoscopy) and correlation between SEF95 and propofol plasma concentration at steady state. Dixon's up-down method was used to determine target SEF95 for each clinical endpoint. Centered isotonic regression determined the dose-response function of SEF95 where 50% and 90% of infants (ED50 and ED90) did not respond to the clinical endpoint. Linear mixed-effect model determined the association of propofol plasma concentration and SEF95. RESULTS: Of 49 enrolled infants, 44 evaluable (90%) showed distinct SEF95 for endpoints: pacifier (ED50, 21.4 Hz; ED90, 19.3 Hz), electrical stimulation (ED50, 12.6 Hz; ED90, 10.4 Hz), and laryngoscopy (ED50, 8.5 Hz; ED90, 5.2 Hz). From propofol 0.5 to 6 μg/ml, a 1-Hz SEF95 increase was linearly correlated to a 0.24 (95% CI, 0.19 to 0.29; P < 0.001) μg/ml decrease in plasma propofol concentration (marginal R2 = 0.55). CONCLUSIONS: SEF95 can be a biomarker for propofol anesthesia depth in infants, potentially improving dosing accuracy and utilization of propofol anesthesia in this population.
引用
- Yuan I, Garcia-Marcinkiewicz AG, Zhang B, et al. Electroencephalographic Indices for Clinical Endpoints during Propofol Anesthesia in Infants: An Early-phase Propofol Biomarker-finding Study. Anesthesiology. 2024. PMID: 38718376. doi:10.1097/ALN.0000000000005043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。